company background image
BIO.B logo

Bio-Rad Laboratories NYSE:BIO.B Stock Report

Last Price

US$332.20

Market Cap

US$9.9b

7D

0%

1Y

-28.4%

Updated

22 Mar, 2024

Data

Company Financials +

Bio-Rad Laboratories, Inc.

NYSE:BIO.B Stock Report

Market Cap: US$9.9b

BIO.B Stock Overview

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.

BIO.B fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Bio-Rad Laboratories, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bio-Rad Laboratories
Historical stock prices
Current Share PriceUS$332.20
52 Week HighUS$467.95
52 Week LowUS$271.00
Beta0.87
1 Month Change-5.87%
3 Month Change3.60%
1 Year Change-28.42%
3 Year Change-42.66%
5 Year Change9.64%
Change since IPO13,646.21%

Recent News & Updates

Recent updates

Bio-Rad: Sartorius Arb Trade Has Fully Unwound, For Now

Jul 12

Shareholder Returns

BIO.BUS Life SciencesUS Market
7D0%1.0%2.1%
1Y-28.4%5.9%30.4%

Return vs Industry: BIO.B underperformed the US Life Sciences industry which returned 6.8% over the past year.

Return vs Market: BIO.B underperformed the US Market which returned 31.1% over the past year.

Price Volatility

Is BIO.B's price volatile compared to industry and market?
BIO.B volatility
BIO.B Average Weekly Movementn/a
Life Sciences Industry Average Movement7.2%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: BIO.B has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BIO.B's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19528,030Norman Schwartzhttps://www.bio-rad.com

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Bio-Rad Laboratories, Inc. Fundamentals Summary

How do Bio-Rad Laboratories's earnings and revenue compare to its market cap?
BIO.B fundamental statistics
Market capUS$9.94b
Earnings (TTM)-US$637.32m
Revenue (TTM)US$2.67b

3.8x

P/S Ratio

-15.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIO.B income statement (TTM)
RevenueUS$2.67b
Cost of RevenueUS$1.24b
Gross ProfitUS$1.43b
Other ExpensesUS$2.07b
Earnings-US$637.32m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-22.35
Gross Margin53.56%
Net Profit Margin-23.86%
Debt/Equity Ratio13.6%

How did BIO.B perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.